CalciMedica is trading 10.67% down at $1.34, amid broader biotech and market weakness, with no verified company-specific announcement identified for October 8.
- Biotech ETF XBI was reported down 2.04%, while the Nasdaq was also lower.
- A September 30 filing allows up to $25 million in stock sales through an at-the-market program.
- The filing is not confirmed as the cause; available evidence favors sector and market pressure over a clear company catalyst.